# Huntington's Disease Neuroimaging & Biomarker Analytics | IXICO

IXICO provides specialist neuroimaging, biomarker, and diagnostics analysis for Huntington's disease clinical trials. Explore our HD research and imaging capabilities.

# Huntington's Disease (HD) Neuroimaging & Biomarker Analysis

![HD Left Dark](/assets/element-images/HD-Left-Dark__FitMaxWzk2MCw1NDBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp "HD Left Dark")

IXICO excels in delivering HD imaging using advanced imaging biomarkers that quantify key HD measurements, such as caudate nucleus and putamen atrophy, white matter integrity changes, and striatal susceptibility changes. Used in combination with the IXI™ Platform, this enhances our accuracy and efficacy for measuring disease-specific changes in brain region volumetrics.

With a proven track record in HD clinical trials and collaborations with key scientific institutions, such as University College London (UCL) and the CHDI Foundation, IXICO’s combination of disease-specific approaches, tools and technologies, together with deep scientific expertise, has enabled IXICO to build a reputation as the trusted partner for HD clinical trials.

### Quantitative Imaging Endpoints

Diffusion MRI (Tensor Imaging, Neurite Orientation Dispersion and Density Imaging, Free Water Imaging, Structural Connectivity) Magnetic Resonance Spectroscopy (MRS) for brain metabolic levels, Quantitative Susceptibility Mapping (QSM) to measure regional susceptibility Functional Connectivity and Metabolism.

### Neuroimaging Biomarker

Regional brain atrophy (Caudate Nucleus, Putamen, Whole Brain, Lateral Ventricles).

## HD Content Portal

### Our HD Factsheet

[    Download ](/assets/downloads/IXICO-Your-Partner-in-Huntingtons-Disease-Imaging-Analysis-and-Operations-Solutions-Jan-2025-2.pdf)

### Poster

Comparison of two natural history studies as part of the HD-IH consortium Presented at HDTC 2025

[    View Here ](/news-and-resources/publications/comparison-of-two-natural-history-studies-as-part-of-the-hd-ih-consortium-a-use-case-for-historical-external-control-group-matching-in-clinical-trials/)

### Research Article

Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press

[    View Here ](/news-and-resources/publications/neuroimaging-to-facilitate-clinical-trials-in-huntingtons-disease-current-opinion-from-the-ehdn-imaging-working-group-ios-press/)

### Poster

Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline Presented at EHDN 2024

[    View Here ](/news-and-resources/publications/comparison-of-local-amyloid-pet-uptake-patterns-between-black-and-white-participants-in-the-gap-bio-hermes-study/)

### Poster

Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants Presented at HDTC 2023

[    View Here ](/news-and-resources/publications/association-between-regional-volume-change-and-clinical-change-in-huntingtons-disease-hd-iss-stage-2-and-stage-3-participants/)

## Recent HD Scientific Publications

**Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials**

- **Date:** March 11th 2025
- **Presentation type:** Presentation at the EHDN conference
- **Synopsis:** This study demonstrates how historical data from TRACK-HD and PREDICT-HD can be merged to form a matched external comparator group for Huntington’s disease using imaging and clinical endpoints.
- **Therapeutic Indication:** Huntington's Disease (HD)

[**>View Study**](/assets/blog-images/Comparison-of-two-natural-history-studies-as-part-of-the-HD-IH-consortium-a-use-case-for-historical-external-control-group-matching-in-clinical-trial.png)

**Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline**

- **Date:** September 2nd 2024
- **Presentation type:** Presentation at the HDTC conference
- **Synopsis:** Data from TRACK-HD/ON and PREDICT-HD,processed within the HD Imaging Harmonization consortium, were analyzed using deep-learning and gBSI methods.
- **Therapeutic Indication:** Huntington's Disease (HD)

[**>View Study**](/assets/blog-images/Volumetric-change-across-the-different-Stages-of-the-Huntingtons-disease-Integrated-Staging-System-HD-ISS-defined-at-baseline.png)

**Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants**

- **Date:** March 12th 2024
- **Synopsis:** This study demonstrates how historical data from TRACK-HD and PREDICT-HD can be merged to form a matched external comparator group for Huntington’s disease using imaging and clinical endpoints.
- **Therapeutic Indication:** Huntington's Disease (HD)

[**>View Study**](/assets/downloads/Association-between-regional-volume-change-and-clinical-change-in-Huntingtons-disease-HD-ISS-Stage-2-and-Stage-3-participants.pdf)

**Validation of IXIQ.Ai+gBSI : an automated framework for caudate atrophy measurement in Huntington’s disease**

- **Date:** May 4th 2023
- **Synopsis:** Validation on 581 MRI scans from TRACK-HD and TRACK-ON HD demonstrated IXIQ.Ai + gBSI’s comparable sensitivity to manual methods in detecting disease progression over time.
- **Therapeutic Indication:** Huntington's Disease (HD)

[**>View Study**](/assets/downloads/Validation-of-IXIQ.Ai+gBSI-an-automated-framework-for-caudate-atrophy-measurement-in-Huntingtons-disease-HDTC-2023-Poster.pdf)